Study Shows New Drug May Boost Non-Hodgkin’s Lymphoma Survival, According to the Non-Hodgkin’s Lymphoma Center

Targeted drug aims to address high recurrence and lower survival in people with B-cell cancers.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Drug May Boost NHL Chemotherapy

SNS01-T...synergizes with the current therapies bortezomib and lenalidomide to inhibit tumor progression.

Raleigh, NC (PRWEB) March 10, 2014

The Non-Hodgkin’s Lymphoma Center is reporting on new published research on an experimental Non-Hodgkin’s Lymphoma drug that appears to boost the power of existing medications.

SNS01-T is a mixture of nanoparticles designed to interfere with the inner workings of malignant B-cells in patients with Non-Hodgkin’s Lymphoma and other B-cell cancers. A new study on the compound in Molecular Therapy, the official journal of the American Society of Gene Therapy, finds that it has the power to induce apoptosis (programmed cell death) in cancer B-cells, especially if it is combined with the active ingredients in two popular Non-Hodgkin’s Lymphoma drugs, Revlimid (lenalidomide) and Velcade (bortezomib).

Researchers in Canada and New Jersey who conducted the laboratory and animal tests on SNS01-T say the compound was taken up by several kinds of cancerous B-cells, including multiple myeloma, the second most common hematological malignancy after Non-Hodgkin’s Lymphoma. At higher doses, the drug was also found to inhibit tumor growth up to 90% in animals with diffuse large B-cell lymphoma, the most common type of Non-Hodgkin’s Lymphoma in adults. Importantly, it did not have a significant effect on normal B-cells.

“In this study we show that SNS01-T is preferentially taken up by malignant B-cells, inhibits tumor growth in multiple animal models of B-cell cancers without damaging normal tissues, and synergizes with the current therapies bortezomib and lenalidomide to inhibit tumor progression,” the authors write in a summary of their research.

When a combination of SNS01-T and Revlimid was given to mice with Non-Hodgkin’s Lymphoma, all of them survived, compared to just 20% for Revlimid alone. Sixty-seven percent of the animals experienced eradication of their cancer after a single 6-week cycle of the combination and, at 8 weeks, there was no recurrence of Non-Hodgkin’s Lymphoma or the other cancers tested. The combination of SNS01-T and Velcade reportedly inhibited cancer growth in the mice by 89%, compared to 39% for Velcade alone.

The original study results were published in Molecular Therapy. (Francis, SM, “SNS01-T modulation of 3lF5A inhibits B-cell cancer progression an synergizes with bortezomib and lenalidomide”, February 26, 2014, Molecular Therapy, Epub ahead of print, http://www.ncbi.nlm.nih.gov/pubmed/?term=SNS01-T)

The Non-Hodgkin’s Lymphoma Center is part of the Cancer Monthly organization. The Non-Hodgkin’s Lymphoma Center has been established by Cancer Monthly to provide more comprehensive information on the causes, diagnosis, and treatments for the many different subtypes of Non-Hodgkin’s Lymphoma. For over ten years, Cancer Monthly has been the only centralized source of cancer treatment results. Patients can see the actual survival rate, quality-of-life indicators, and other key data for approximately 1,500 different cancer treatments. Cancer Monthly provides timely and ground-breaking news on the causes, diagnoses and treatments of the most common cancers including Bladder, Brain, Breast, Colon, Kidney (Renal), Liver, Lung (NSCLC), Ovarian, Prostate, and Rectal Cancers, Melanoma, Mesothelioma, and Non-Hodgkin's Lymphoma. Written for patients and their loved ones, Cancer Monthly helps families make more informed treatment decisions.


Contact

Follow us on: Contact's Google Plus